Increase therapy-related leukemia secondary to breast cancer

Leukemia

Volumn 14, Issue 6, 2000, Pages 1014-1017

  Carli, P M ^a   Sgro, C ^b   Parchin Geneste, N ^b   Isambert, N ^c   Mugneret, F ^b   Girodon, F ^a   Maynadie M ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b HÔPITAL DU BOCAGE   (France)

^c Medical University of Dijon   (France)

Author keywords

Breast cancer; Epidemiology; Mitoxantrone; Promyelocytic leukemia; Secondary acute myeloid leukemia

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GYRASE INHIBITOR; MITOXANTRONE; NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RETINOIC ACID; TAMOXIFEN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CONTROLLED STUDY; FEMALE; FRANCE; HUMAN; KARYOTYPE; LEUKEMIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REFRACTORY ANEMIA;

EID: 0034084812     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401787     Document Type: Article

References (20)

1. Whitlock JA, Greer JP, Lukens JN. Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia. Cancer 1991; 68: 600-604.
2. Pedersen Bjergaard J, Specht L, Larsen SO, Ersbil J, Struck J, Hansen MM, Hanse HH, Nissen NI. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 1987; 2: 83-88.
3. Curtis RE, Boice JD Jr, Moloney WC, Ries LG, Flannery JT. Leukemia following chemotherapy for breast cancer. Cancer Res 1990; 50: 2741-2746.
4. Thirman MJ, Larson RA. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am 1996; 10: 293-320.
5. Bahtia MJ, Davies SM, Robinson LL. Leukemia. In: Neugut AI, Meadows AT, Robinson E (eds). Multiple Primary Cancers. Lippincott Williams & Williams: New York, 1999, pp 257-276.
6. Laughlin MJ, McGaughey DS, Crews JR, Chao NJ, Rizzieri D, Ross D, Gockerman J, Cirrincione C, Berry D, Mills L, Defusco P, Legrand S, Peters WP, Vredenburg JJ. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. J Clin Oncol 1998; 16: 1008-1012.
7. Kumpulainen EJ, Hirvikoski PP, Pukkala E, Johansson RT. Cancer risk after adjuvant chemo- or chemohormonal therapy of breast cancer. Anticancer Drugs 1998; 9: 131-134.
8. Linassier C, Barin C, Bremond JL. Secondary leukaemia in breast cancer patients after exposure to an association of mitoxantrone, fluorouracil, cyclophosphamide and radiotherapy. Proc Am Soc Clin Oncol 1996; 15: 360-363.
9. Pedersen Bjergaard J, Sigsgaard TC, Nielsen D, Gjedde SB, Philip P, Hansen M, Larsen O, Mouridsen H, Dombernowsky P. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epidoxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol 1992; 10: 1444-1451.
10. Carli PM, Milan C, Lange A, Devilliers E, Guy H, Faivre J. Haematopoietic malignancies in Côte d'Or (France): a population based study. Br J Cancer 1986; 53: 811-815.
11. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
13. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield C. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting, Airlie House, Virginia, November, 1997. J Clin Oncol 1999; 17: 3835-3849.
14. Mitelman F, Kargers S, Basel P. An International System for Human Cytogenetic Nomenclature. ISCN, 1995.
15. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Ped Oncol 1994; 23: 86-98.
16. Dissing M, Le Beau MM, Pedersen Bjergaard J. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors? J Clin Oncol 1998; 16: 1890-1896.
17. Hoffmann L, Mö P, Pedersen Bjergaard J, Waage A, Pedersen M, Hirsch FR. Therapy-related acute promyelocytic leukemia with t(15;17)(q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature. Ann Oncol 1995; 6: 781-788.
18. Detourmignies L, Castaigne S, Stoppa AM, Harousseau JL, Sadoun A, Janvier M, Demory JL, Sanz M, Berger R, Bauters F. Therapy-related acute promyelocytic leukemia: a report on 16 cases. J Clin Oncol 1992; 10: 1430-1435.
19. Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flamery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. New Engl J Med 1992; 326: 1745-1751.
20. Ellis M, Ravid M, Lishner M. A comparative analysis of alkylating agent and epipodophyllotoxin-related leukemias. Leuk Lymphoma 1993; 11: 9-13.